Endoplasmic reticulum-associated amyloid ␤-peptide (A␤)-binding protein (ERAB)/L-3-hydroxyacyl-CoA dehydrogenase type II (HADH II) is expressed at high levels in Alzheimer's disease (AD)-affected brain, binds A␤, and contributes to A␤-induced cytotoxicity. Purified recombinant ERAB/HADH II catalyzed the NADH-dependent reduction of S-acetoacetyl-CoA with a K m of Ϸ68 M and a V max of Ϸ430 mol/min/mg. The contribution of ERAB/HADH II enzymatic activity to A␤-mediated cellular dysfunction was studied by site-directed mutagenesis in the catalytic domain (Y168G/K172G). Although COS cells cotransfected to overexpress wild-type ERAB/ HADH II and variant ␤-amyloid precursor protein (␤APP(V717G)) showed DNA fragmentation, cotransfection with Y168G/K172G-altered ERAB and ␤APP(V717G) was without effect. We thus asked whether the enzyme might recognize alcohol substrates of which the aldehyde products could be cytotoxic; ERAB/HADH II catalyzed oxidation of a variety of simple alcohols (C2-C10) to their respective aldehydes in the presence of NAD ؉ and NAD-dependent oxidation of 17␤-estradiol. Addition of micromolar levels of synthetic A␤(1-40) to purified ERAB/HADH II inhibited, in parallel, reduction of Sacetoacetyl-CoA (K i Ϸ 1.6 M), as well as oxidation of 17␤-estradiol (K i Ϸ3.2 M) and (؊)-2-octanol (K i Ϸ 2.6 M). Because micromolar levels of A␤ were required to inhibit ERAB/HADH II activity, whereas A␤ binding to ERAB/HADH II occurred at much lower concentrations (K m Ϸ 40 -70 nM) , the latter more closely simulating A␤ levels within cells, A␤ perturbation of ERAB/HADH II was likely to result from mechanisms other than the direct modulation of enzymatic activity. Cells cotransfected to overexpress ERAB/HADH II and ␤APP(V717G) generated malondialdehyde-protein and 4-hydroxynonenal-protein epitopes, which were detectable only at the lowest levels in cells overexpressing either ERAB/HADH II or ␤APP(V717G) alone. Generation of such toxic aldehydes was not observed in cells contransfected to overexpress Y168G/K172G-altered ERAB and ␤APP(V717G).
Recent studies of mutations underlying familial Alzheimer's disease have strengthened links between amyloid ␤-peptide (A␤) 1 and the pathogenesis of this devastating neurodegenerative disorder (1) (2) (3) (4) (5) (6) . Most work analyzing toxic effects of A␤ on cellular properties has employed high concentrations of A␤ fibrils that are thought to nonspecifically injure cells by destabilizing cell membranes (1, 4, 6 -9) . We have hypothesized, however, that early in Alzheimer's disease (AD), when levels of A␤ are much lower, the amyloidogenic peptide might interact with particular cellular target molecules, thereby magnifying the capacity of A␤ to perturb cellular functions (10 -14) . At the cell surface, receptors, for example, receptor for advanced glycation end products (RAGE), the p75 component of the neurotrophin receptor, and the macrophage scavenger receptor, are such molecular targets of A␤ (10 -14) . Another potential cellular interaction site is the endoplasmic reticulum-associated A␤-binding protein, initially designated ERAB and first identified using the yeast two-hybrid system to screen for species that bound A␤ (15) . ERAB was localized to the endoplasmic reticulum and mitochondria in cultured cells (15) . Its expression was found to be increased in AD brain, and, in vitro, ERAB facilitated A␤ cytotoxicity in neuroblastoma and transfected COS cells. Our initial analysis of the ERAB amino acid sequence showed resemblance to the family of short-chain alcohol dehydrogenases, including hydroxysteroid dehydrogenases, Ke6, and acetoacetyl coenzyme A (CoA) reductases (16) . These results suggested a primary role for ERAB in cell metabolism, in addition to having the potential to contribute to A␤-induced cytotoxicity.
The bovine counterpart of ERAB was recently isolated from liver mitochondrial preparations, and characterized as the mitochondrial 3-hydroxyacyl-CoA dehydrogenase type II (HADH II) (E.C. 1.1.1.35) (17, 18) , a participant in the third reaction of the fatty acid ␤-oxidation spiral (19, 20) . This identification is consistent with a recent report concerning properties of a human L-3-hydroxyacyl-CoA dehydrogenase (21) , the cDNA sequence of which is identical to that of human ERAB. 2 Although consequences of ERAB/HADH II deficiency are not known, heritable disorders with defects in fatty acid ␤-oxidation have been identified (19, 20) . These patients have hepatomegaly, cardiomegaly, encephalopathies, peripheral neuropathy, rhabdomyolysis, and myoglobinuria, suggesting a role for fatty acid ␤-oxidation enzymes in the metabolic balance of a range of organs.
To investigate whether the enzymatic activity of ERAB/ HADH II was correlated with its interaction with A␤ and cytotoxicity, we have further characterized this protein. We find that it has the ability to catalyze the oxidation of alcohol groups in a range of substrates, including linear alcohols and estradiol, as well as the reduction of S-acetoacetyl-CoA. To analyze the role of ERAB/HADH II enzymatic activity in potentiation of A␤ toxicity, a catalytically crippled form was prepared containing two substitutions in the highly conserved sequence of residues 168 -172 (YSASK), putatively assigned as part of the active center of the enzyme (16) . Cells overexpressing mutant ERAB were relatively protected from A␤ cytotoxicity consequent to overexpression of mutant ␤APP(V717G), as demonstrated by suppression of apoptosis. In contrast, cells overexpressing both wild-type ERAB/HADH II and ␤APP (V717G) suffered increased cytotoxicity. Thus, it appears that activity of the enzyme is necessary for full toxicity. In cells overexpressing ERAB/HADH II and ␤APP(V717G), the intracellular distribution of ERAB/HADH II was altered, and generation of reactive aldehydes, including malondialdehyde and 4-hydroxynonenal, occurred. Such reactive aldehydes provide a barometer of oxidant cell stress (22) (23) (24) (25) and have been observed in the brain of AD patients (26 -32) . These data lead us to propose that enzymatically active ERAB/HADH II, an alcohol dehydrogenase with broad substrate specificity, may have a role in metabolic homeostasis but can switch to a pathologic role in an A␤-rich environment, as in AD, potentiating cell stress and cytotoxicity.
EXPERIMENTAL PROCEDURES
Preparation of Wild-type and Mutant Forms of ERAB-Escherichia coli (BL21) was transformed with pGE5-human ERAB/HADH II or mutant forms of ERAB/HADH II, prepared as described below. Transformants were induced with 0.5 mM isopropyl-1-thio-␤-D-galactopyranoside for 3 h, and cell extracts were prepared by cell disruption. Extracts were subjected to cation exchange FPLC chromatography on SP Sepharose Fast Flow (Amersham Pharmacia Biotech) and on Source 15S, followed by gel filtration on Superdex 200. The extract from ϳ1 liter of bacterial culture was applied to 2 ml of SP Sepharose in 25 mM MES (pH 6.0), 50 mM NaCl, 5 mM dithiothreitol. The resin was washed with equilibration buffer and eluted with an ascending linear salt gradient (0.1-1.0 M NaCl). ERAB/HADH II, detected by its migration on SDS-PAGE and by immunoblotting (see below), eluted in fractions corresponding to 0.15-0.4 M NaCl. These fractions were pooled, diluted 6-fold, and applied to Source 15S resin in 0.1 M MES (pH 6.0)/0.1 M NaCl (5 mg of protein per 1 ml of resin). The column was eluted with an ascending salt gradient, and ERAB/HADH II emerged at Ϸ0.15 M NaCl. ERAB/HADH II-rich fractions were concentrated by ultrafiltration to Ϸ15 mg/ml and loaded onto a Superdex 200 (30/10) column (1 ml was applied to the column for each run). Peak fractions from Superdex 200 were subjected to SDS-PAGE (12%) and immunoblotting. Immunodetection of ERAB/HADH II employed as primary antibody either anti-ERAB peptide IgG (15) or antibody prepared in rabbits, according to standard methods (33), using full-length recombinant human ERAB/ HADH II as the immunogen. IgG was purified from rabbit antisera by chromatography on Protein A-Sepharose CL-4B (Amersham Pharmacia Biotech). Sites of primary antibody binding were visualized with peroxidase-conjugated goat anti-rabbit IgG (Sigma). The ERAB/HADH II immunoreactive band migrated with Ϸ27 kDa, consistent with previous observations (15, 17, 18, 21) . N-terminal sequencing of wild-type and mutant forms of ERAB/HADH II was performed on a Porton 2090 E gas phase protein sequencer (Beckman) equipped with an on-line Hewlett-Packard 1090 HPLC. Site-directed mutagenesis was employed to mutate tyrosine (168) and/or lysine (172) to glycine using a kit from Promega (Madison, WI).
Assays of ERAB Enzymatic Activity and A␤ Binding-ERAB/HADH II was studied for its activity to reduce S-acetoacetyl-CoA, as well as its capacity to dehydrogenate alcohol groups in a range of linear alcohols and in estradiol. The assay for reduction of S-acetoacetyl-CoA employed ERAB/HADH II (333 ng/ml), a range of S-acetoacetyl-CoA concentrations (0.0015-0.36 mM; Sigma), and NADH (0.1 mM; Sigma) in 97 mM potassium phosphate (pH 7.3). The reaction was run for a total of 2 h at 25°C under steady-state conditions (34) , and the change in NADH absorbance at 340 nm was determined every 5 min. Alcohol dehydrogenase assays employed ERAB/HADH II (20 g/ml), a range of alcohol substrates and concentrations (methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, (Ϯ)-2-octanol, (ϩ)-2-octanol, (Ϫ)-2-octanol, and n-decanol; Sigma), and NAD ϩ (7.5 mM) in 22 mM sodium pyrophosphate, 0.3 mM sodium phosphate (pH 8.8). The reaction was run for 2 h at 25°C, and the absorbance at 340 nm was monitored every 5 min as described above. Studies to evaluate oxidation 2 ERAB was the name applied to HADH II before their identity was ascertained. The designation ERAB/HADH II is used to emphasize the properties of ERAB with respect to binding of A␤ and potentiation of A␤ toxicity, as well as its metabolic function as a 3-hydroxyacyl-CoA dehydrogenase. We propose to rename the enzyme A␤ binding alcohol dehydrogenase as this reflects both its capacity to bind A␤ and its activity as a generalized alcohol dehydrogenase (see text).
FIG. 1. Characterization of E. coli-derived ERAB/HADH II.
A, nonreduced (lane 1) and reduced (lane 2) SDS-PAGE (12%) of purified recombinant ERAB/HADH II (1 g/lane). Protein was visualized by Coomassie Blue staining. Standard proteins were run simultaneously, and their migration is indicated by the bars on the far left. Each bar is labeled with the corresponding molecular mass in kDa. B. Immunoblotting. Purified recombinant ERAB/HADH II was subjected to reduced SDS-PAGE (12%) followed by immunoblotting. ERAB antigen was visualized using rabbit anti-full-length recombinant ERAB/HADH II IgG (3.5 g/ml) (lane 1), followed by application of secondary antibody and the detection system. In lane 2, excess soluble ERAB/HADH II (50-fold molar excess over the amount of primary antibody) was added during incubation of blots with the primary antibody. In lane 3, ERAB/HADH II was present on the membrane (as in lane 1), but the same amount preimmune IgG was used in place of immune IgG. Details of procedure are described in the text. of 17␤-estradiol employed ERAB/HADH II (30 g/ml), a range of 17␤estradiol concentrations (3.8 -92 M), and NAD ϩ (0.4 mM) in 20 mM sodium pyrophosphate (pH 8.9) at 25°C for 2 h. Where indicated, freshly prepared synthetic A␤ or A␤(1-42), either obtained from California Peptide Inc. (Napa, CA) and purified by reversed-phase and size exclusion high pressure liquid chromatography (purity was confirmed by mass spectrometry, amino acid analysis and peptide mapping) or purchased in purified form from QCB (Hopkinton, MA) was added to the reaction mixture. A␤ was freshly prepared and dissolved in distilled water. A␤ was also freshly prepared and dissolved in Me 2 SO. The final concentration of Me 2 SO was Ͻ1%, and control experiments using this concentration of Me 2 SO alone (i.e. without A␤(1-42)) had no effect on the reactions under study. Kinetic data were analyzed by PRISM (Scitech, San Diego, CA) to determine K m , V max , and K i , and lines shown in the figures represent theoretical curves according to kinetic parameters calculated by the program. One unit of enzyme activity was defined as that converting 1.0 mol of substrate to product per min. For K i , a one-site competitive inhibition model was used (34) .
Binding of ERAB/HADH II to A␤ was studied using 125 I-labeled purified recombinant ERAB/HADH II (15) . The protein was labeled by the Iodobead method to a final specific radioactivity of Ϸ2000 cpm/ng (an average of five labelings) and the tracer was Ͼ90% precipitable in trichloroacetic acid (10%). Wells were incubated overnight at 4°C with A␤(1-40) diluted into carbonate buffer (0.1 M; pH 9.6). Excess sites in the well were blocked with phosphate-buffered saline containing fatty acid-free bovine serum albumin (10 mg/ml) for 2 h at 37°C. Wells were aspirated, and binding buffer (minimal essential medium containing fatty acid-free bovine serum albumin, 1 mg/ml; 0.05 ml) was added with 125 I-ERAB/HADH II alone or in the presence of 100-fold excess unlabeled ERAB/HADH II. Binding was allowed to proceed for 2 h at 37°C, and each well was washed four times (0.2 ml/wash) over 30 s with ice cold phosphate-buffered saline containing Tween 20 (0.05%). Bound tracer was eluted with Nonidet P-40 (1%) over 5 min at 37°C. Specific binding was defined as total minus nonspecific binding. Total binding was that observed in the presence of tracer alone. Nonspecific binding was that observed with tracer in the presence of 100-fold excess unlabeled ERAB/HADH II. Binding experiments were performed with four replicates per concentration of tracer. Data were analyzed by nonlinear least squares analysis (Enzfitter) using a one-site model by the method of Klotz and Hunston (35) .
Cell Transfection Studies-Transient transfection of COS-1 or neuroblastoma (N115) cells (ATCC) employed pcDNA3/human ERAB/ HADH II (wild-type or mutant forms) using LipofectAMINE according to previously described methods (15) . Where indicated, cultures were subjected to transient transfection with pAdlox/␤APP(V717G). The latter was made by inserting a construct encoding ␤APP(V717G) (36) into the HindIII cloning sites in the pAdlox vector (37) . Alternatively, a construct encoding wild-type (wt) ␤APP(1-695) was inserted into the SalI cloning sites of the pMT vector (38) to make pMT/wt␤APP. ␤APP was detected with rabbit anti-C-terminal ␤APP IgG (369W) generously provided by Dr. Sam Gandy (New York University, New York, NY) (39) .
Assays for DNA Fragmentation and Subcellular Localization-The effect of ERAB/HADH II on cellular properties was determined in the absence and the presence of an A␤-rich environment (the latter provided by transfection with pAdlox/␤APP(V717G)). COS and neuroblastoma cells transiently transfected with pcDNA3/ERAB with or without pAdlox/␤APP(V717G) were assayed for evidence of DNA fragmentation using the ELISA for cytoplasmic histone-associated DNA fragments (Cell Death ELISA; Boehringer Mannheim) and the TUNEL assay (Boehringer Mannheim). Similar experiments were performed employing pMT/wt␤APP in place of ␤APP(V717G). In order to determine the relative apoptosis index (RAI) (15) , cells were also evaluated for expression of ERAB/HADH II or ␤APP immunocytochemically (cells were fixed in 2% paraformaldehyde containing 0.1% Nonidet P-40) using primary antibodies to each antigen and peroxidase-conjugated antirabbit IgG (Sigma) as the secondary antibody, (because both primary antibodies were prepared in rabbits, ERAB/HADH II and ␤APP were detected separately in duplicate cultures; the TUNEL assay was performed on the same cultures in which ERAB/HADH II or ␤APP was visualized.
Subcellular localization of ERAB/HADH II employed ultracentrifugation of disrupted cells and confocal microscopy. Cells (5 ϫ 10 8 ) were transfected as above, and, 12 h later, cells were pelletted and fractionated as described (40) . In brief, cell pellets frozen at Ϫ80°C were thawed, resuspended in 10 ml of Buffer A (0.25 M sucrose; 10 mM HEPES, pH 7.5; 1 mM dithiothreitol; 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin; 0.1 mM 1-chloro-3-tosylamido-7-amino-2-heptanone), and cavitated at 400 p.s.i. for 30 min using a nitrogen cavitation bomb apparatus (Kontes Glass Co., Vineland, NJ). Following cell disruption, the lysate was clarified by centrifugation at 10,000 ϫ g for 15 min at 4°C, and the pellet was resuspended in TNE buffer (10 mM Tris-HCl, pH 8.0; 1% Nonidet P-40; 150 mM NaCl; 1 mM EDTA; 10 g/ml aprotinin; 1 mM phenylmethylsulfonyl fluoride). The latter material was centrifuged and fractionated through a series of sucrose steps (38, 30 , and 20% sucrose prepared in 10 mM HEPES, pH 7.5; 1 mM dithiothreitol) at 100,000 ϫ g for 3 h at 4°C. Layered fractions (fractions 1-4) were collected by puncturing the tube at the desired depth and gently withdrawing the fluid. The pellet at the bottom of the tube was resuspended in 3 ml of Buffer A (precipitate fraction, termed fraction 5). Following determination of protein content, each fraction (5 g protein/lane) was subjected to Western blotting using anti-ERAB/ HADH II IgG. Enrichment of cellular structures/organelles in subcellular fractions was identified by the presence of marker proteins: RAGE (control cultures were transfected with pcDNA3/RAGE that was detected by Western blotting using specific antibodies to RAGE (10) in order to identify the plasma membrane-rich fraction), GRP78/Bip (endoplasmic reticulum; StressGen; Victoria, Canada) (40) , and cytochrome c (mitochondria; StressGen). The mitochondria-rich fraction was also prepared using the method of Du et al. (41) .
Confocal microscopy (Zeiss) employed rabbit anti-human ERAB/ HADH II IgG, monoclonal antibody to protein disulfide isomerase (PDI) (StressGen) and a specific marker for mitochondria (Mito-Tracker TM Red CMXRos, Molecular Probes, Eugene, OR). For detection of malondialdehyde (MDA) and 4-hydroxynonenal (HNE) epitopes, murine monoclonal anti-MDA-lysine IgG (1 g/ml; MDA2) and murine monoclonal anti-HNE-lysine IgG (1 g/ml; NA59) were used, respectively (22) (23) (24) (25) . Antibodies were generated in the Immunology Core of the La The same concentration of wild-type and mutant ERAB was used in each case. A, ERAB/HADH II (0.33 g/ml) was incubated with the indicated concentration of S-acetoacetyl-CoA and NADH (0.1 mM). B, ERAB/HADH II (20 g/ml) was incubated with the indicated concentration of (Ϫ)-octanol and NAD ϩ (7.5 mM). C, ERAB/HADH II (30 g/ml) was incubated with the indicated concentration of 17␤-estradiol and NAD ϩ (0.4 mM). The velocity (V) of the reaction (units/mg of protein) is plotted versus added substrate concentration. Details of the experimental methods are described in the text. The broken line represents the theoretical curve according to the K m and V max values (see Table I ) calculated by the computer program. Experimental procedures are described in the text.
Jolla SCOR in Molecular Medicine and Atherosclerosis and were kindly supplied by Dr. Joe Witztum (University of California, San Diego, CA). Cultures were fixed using 4% paraformaldehyde plus 5% sucrose (pH 7.4) containing 50 M butylated hydroxytoluene and 1 mM EDTA (22) (23) . Sites of primary antibody binding were visualized by addition of rhodamine-conjugated goat anti-mouse IgG (Sigma). Confocal microscopy images were quantitated using the National Institutes of Health Image program.
RESULTS

Characterization of Recombinant Wild-type and Mutant
Forms of ERAB/HADH II-E. coli was transformed with a plasmid encoding wt human ERAB/HADH II, and lysates were prepared. The recombinant protein was purified by sequential SP Sepharose and Source 15S chromatography, followed by gel filtration on Superdex 200. The final material was homogeneous on SDS-PAGE, displaying a single band migrating at an apparent molecular mass of Ϸ27 kDa (Fig. 1A) , and, on amino acid sequencing, only the N-terminal sequence of ERAB/HADH II was obtained: Ala-Ala-Ala-Cys-Arg-Ser-Val-Lys-Gly Leu-Val-Ala-Val-Ile-Thr-Gly-Gly-Ala-Ser-Gly-Leu. Immunoblotting with anti-human ERAB IgG (Fig. 1B, lane 1) confirmed the presence of ERAB/HADH II epitopes in the recombinant ERAB/HADH II preparations. Addition of excess free ERAB/ HADH II during incubation of blots with the primary antibody prevented appearance of the ERAB/HADH II-immunoreactive band (Fig. 1B, lane 2) . Preimmune antibody did not visualize the ERAB/HADH II band on blots (Fig. 1B, lane 3) .
Initial comparison with Swiss-Prot and Protein Data Bank using the FASTA algorithm indicated that the ERAB sequence most closely resembled the family of short-chain alcohol dehydrogenases, including hydroxysteroid dehydrogenases and acetoacetyl-CoA reductases (15) . Studies of bovine HADH II, the bovine counterpart of ERAB, demonstrated that it possesses 3-hydroxyacyl-CoA dehydrogenase activity, catalyzing both forward and reverse reactions (18) . In this work, we show that in the presence of NADH, ERAB reduced S-acetoacetyl-CoA with a K m of Ϸ68 M and a V max of Ϸ430 units/mg ( Fig. 2A and Table  I) . These values are similar to bovine HADH type II (K m of Ϸ20 M and V max of Ϸ530 units/mg) (18) , and to those of human HADH type II (HADH II) described in a report published during preparation of our manuscript (21) . Thus, ERAB is an HADH and, based on amino acid sequence, is identical to human HADH type II. However, the interaction of ERAB with A␤ results in quite unexpected properties compared with what might be expected for a metabolic enzyme, leading us to term it Protein was visualized by Coomassie Blue staining. A, right two lanes, SDS-PAGE of ERAB/mutERAB (as above) followed by immunoblotting with anti-ERAB/HADH II IgG. Migration of simultaneously run molecular mass markers is indicated on the left in kilodaltons (kD). B, binding of 125 I-ERAB/HADH II to A␤ . Wells were incubated with A␤ (5 g/ml), followed by blocking excess sites in the well with albumin-containing buffer and then addition of 125 I-ERAB/HADH II (either wild-type or mutERAB) alone or in the presence of 100-fold molar excess of unlabeled ERAB/HADH II (either wild-type or mutERAB). Specific binding (total minus nonspecific binding) is plotted versus added ERAB/HADH II (nM). The broken line shows the best-fit line by nonlinear least squares analysis. ERAB/HADH II (to emphasize A␤-induced modulation of its properties, see below). These data suggested the importance of determining the contribution of ERAB/HADH II enzymatic activity to its role in potentiation of A␤ cytotoxicity.
ERAB/HADH II Activity Is Essential for Promotion of A␤ Cytotoxicity-Tyr 168 and Lys 172 are part of a highly conserved sequence (residues 168-172) that has been putatively assigned as part of the active site of the enzyme (16) . Thus, to prepare an active siteblocked form of human ERAB/HADH II, we mutated these residues simultaneously or separately by site-directed mutagenesis to Gly. Mutant (mut) ERAB(Y168G/K172G) was expressed in E. coli and purified as described above for wtERAB/HADH II. The final material was homogeneous on SDS-PAGE ( Fig. 3A, two left lanes) , migrated virtually identically with wtERAB/HADH II, had the expected N-terminal sequence (data not shown), and was immunoreactive with anti-ERAB IgG (Fig. 3A, two right lanes) . Purified mutERAB(Y168G/K172G) was devoid of activity toward S-acetoacetyl-CoA ( Fig. 2A) , as well as octanol and 17␤-estradiol (Fig. 2 , B-C; see below). However, mutERAB bound A␤ in a manner comparable to wild-type ERAB (Fig. 3B) ; apparent K d values for ERAB/ HADH II binding to immobilized A␤(1-40) were 64.5 Ϯ 9.0 and 38.9 Ϯ 9.3 nM for wild-type and mutant ERAB/HADH II, respec- . Forty-eight hours later, the TUNEL assay was performed. D, RAI. Cells were transfected/cotransfected with the indicated constructs, and 48 h later, cultures were subjected to the TUNEL assay and immunostained to detect ERAB/HADH II or ␤APP antigen (ERAB/HADH II and ␤APP antigens were determined in duplicate cultures; ERAB/HADH II immunostaining and TUNEL assay, or ␤APP immunostaining and TUNEL assay, were performed on the same slide). The RAI is a percentage denoting the ratio of the number of TUNEL positive nuclei in cells with the indicated antigen divided by the total number of cells with the indicated antigen in the same cell population. RAI 0 indicates the fraction of TUNEL positive nuclei in cells not staining for the transfected antigen divided by the total number of cells not expressing the indicated antigen in the same cell population. The constructs used for transfection/cotransfection are indicated on the far left.
tively. Similar binding of ERAB/HADH II to ␤-amyloid was observed with A␤(1-42) (data not shown). Thus, mutERAB(Y168G/ K172G) was an inactive form of the enzyme that retained the ability to interact with A␤, allowing us to probe the role of ERAB/ HADH II enzymatic activity in potentiation of A␤ cytotoxicity. Similar results were independently obtained with the two other ERAB/HADH II mutants, Y168G and K172G; in each case, the mutant form was devoid of enzymatic activity but retained the capacity to bind A␤.
Recent studies have demonstrated that processing of ␤APP, with generation of A␤, can occur within multiple intracellular compartments (36, (42) (43) (44) (45) (46) , including endoplasmic reticulum, a site where ERAB/HADH II has been localized. In particular, a construct encoding the London mutant of ␤APP(V717G) forms increased levels of A␤(1-42) in endoplasmic reticulum follow-ing transient transfection (36) . This led us to develop a model system using COS and neuroblastoma cells for testing the effects of ERAB/HADH II on A␤-induced cytotoxicity by cotransfection with plasmids causing overexpression of wild-type or mutant ERAB/HADH II and ␤APP(V717G). First, expression of ERAB/HADH II and ␤APP was evaluated under our experimental conditions by immunoblotting using antibody to ERAB/HADH II and C-terminal ␤APP antibody (396W) (39) . COS cells transiently transfected with pAdlox/␤APP(V717G) overexpressed ␤APP antigen (Fig. 4A, upper panel, lanes 3, 5,  and 6 ), compared with controls ( Fig. 4A, upper panel, lanes 1, 2,  4, and 7) , whether cells were cotransfected to overexpress wtERAB or mutERAB (Fig. 4A, upper panel, lanes 3 and 5) or not (Fig. 4A, upper panel, lane 6) . Several closely spaced ␤APPimmunoreactive bands with molecular masses of Ϸ110 -140 
FIG. 6. Subcellular distribution of ERAB/HADH II in neuroblastoma cells following transient transfection with or without ␤APP(V717G).
A-F, neuroblastoma cells were transfected with pcDNA3/wtERAB/HADH II alone, and cultures were stained to visualize ERAB/HADH II ϩ endoplasmic reticulum marker PDI (A), PDI alone (B), ERAB/HADH II alone (C), ERAB/HADH II ϩ mitochondrial marker (D), mitochondrial marker alone (E), or ERAB/HADH II alone (F). G-L, neuroblastoma cells were cotransfected with pcDNA3/wtERAB ϩ pAdlox/ ␤APP(V717G), and cultures were stained to visualize ERAB/HADH II ϩ PDI (G), PDI alone (H), ERAB/HADH II alone (I), ERAB/HADH II ϩ mitochondrial marker (J), mitochondrial marker alone (K), or ERAB/HADH II alone (L). On the left of the figure, the transfected gene products and the antigens visualized by immunostaining are indicated in the corresponding set of three panels. kDa (often coalescing into one broad band) (39) were seen, although more rapidly migrating immunoreactive forms of ␤APP were also observed (Fig. 4A, lane 6) . The latter forms were more evident in cells expressing ␤APP(V717G) alone (Fig.  4A, lane 6) compared with those co-expressing ␤APP(V717G) and wild-type or mutant ERAB/HADH II (although levels of the latter forms were comparable in cells overexpressing wtERAB/HADH II ϩ ␤APP(V717G) or mutERAB/HADH II ϩ ␤APP(V717G)) ( Fig. 4A, lanes 3 and 5) . Similarly, human ERAB/HADH II antigen was overexpressed by COS cells transfected with pcDNA3/wtERAB (Fig. 4A, lower panel, lanes 2 and  3) or pcDNA3/mutERAB (Fig. 4A, lower panel, lanes 4 and 5) , whether cotransfected with pAdlox/␤APP(V717G) (Fig. 4A,  lower panel, lanes 3 and 5) or not (Fig. 4A, lower panel, lanes 2  and 4) . Comparable results were observed in cotransfection studies with neuroblastoma cells, although the absolute amount of the transfected gene products, ␤APP and/or ERAB/ HADH II, was somewhat less in neuroblastoma than in COS cells. Further experiments were performed with COS cells overexpressing wt␤APP following transfection with pMT/ wt␤APP alone or cotransfection with pMT/wt␤APP ϩ wtERAB/ HADH II. Immunoblotting showed wt␤APP (Fig. 4A, upper  panel, lanes 9 and 10) to be expressed at levels comparable to mutant ␤APP (lanes 3, 5, and 6) , whether wtERAB/HADH II was present (lane 9) or not (lane 10). Similarly, cotransfection of COS cells with pMT/wt␤APP did not alter expression of wild-type ERAB/HADH II (Fig. 4A, lower panel, lanes 8 and 9) .
COS cells cotransfected to overexpress wtERAB/HADH II and ␤APP(V717G) displayed increased DNA fragmentation, as shown by ELISA for cytosolic histone-associated DNA fragments ( Fig. 4B ) and TUNEL assay (Fig. 4C , I-III, depicting representative fields of cells overexpressing wtERAB/HADH II alone (I), ␤APP(V717G) alone (III), or wtERABϩ␤APP(V717G) (II)). When COS cells were cotransfected to overexpress wtERAB with wt␤APP (the latter in place of mutant ␤APP), evidence of increased DNA fragmentation was also observed compared with cultures overexpressing either wtERAB or wt␤APP alone (Fig. 4B ). However, somewhat lower levels of DNA fragmentation were observed following overexpression of wt␤APP compared with ␤APP(V717G), consistent with the previously observed higher levels of intracellular A␤ (especially A␤ in endoplasmic reticulum) with this mutant form of ␤APP (36) .
In order to further validate these data, it was necessary to correlate cells expressing the transfected genes (by immunocytochemistry for ERAB/HADH II or ␤APP) with those undergoing nuclear DNA fragmentation (by TUNEL assay). This was especially important, as the transient transfection system employed for these studies has an efficiency of Ϸ20 -25%. For this reason, we utilized a RAI (15) to compare, in the same population, cells successfully transfected to overexpress wild-type/ mutant ERAB/HADH II or ␤APP and those undergoing apoptosis (Fig. 4D) . The RAI denotes a ratio of cells with TUNELpositive nuclei overexpressing ERAB/HADH II (RAI ERAB ) or ␤APP (RAI ␤APP ) divided by the total number of cells expressing either ERAB/HADH II or ␤APP. RAI 0 is the percentage of TUNEL-positive nuclei in cells in the same wells that did not express the transfected gene products, divided by the total number of cells that had negligible levels of these protein products. Cells transfected with pcDNA3/wtERAB alone displayed a low level of DNA fragmentation (RAI ERAB Ϸ 13%), similar to that observed in nontransfected cells in the same wells (RAI 0 Ϸ 8%). Comparable results were observed when cells were transfected to overexpress ␤APP(V717G) alone; RAI ␤APP was low, at Ϸ9%, and RAI ␤APP Ϸ RAI 0 (11%). In contrast, COS cells cotransfected with pcDNA3/wtERAB ϩ pAdlox/␤APP(V717G) had high levels of DNA fragmentation (RAI ERAB Ϸ 64% and RAI ␤APP Ϸ 60%, the latter in separate experiments) compared with unsuccessfully transfected cells in the same well (RAI 0 Ϸ 7%). These data indicate that overexpression of wtERAB along with mutant ␤APP markedly enhanced cellular toxicity compared with either alone. Similar results were observed with neuroblastoma cells. Using this experimental system, the effect of mutERAB (Y168G/K172G), in place of wtERAB/HADH II, was assessed in COS cells overexpressing ␤APP(V717G). As noted above, levels of ERAB/HADH II in COS cells transfected with pcDNA3/mutERAB were comparable to those observed in COS cells transfected with pcDNA3/wtERAB (Fig. 4A, lower panel) . Also, cotransfection of pcDNA3/mutERAB ϩ pAdlox/ ␤APP(V717G) resulted in expression of ␤APP antigen at levels comparable to those seen in cells transfected with the construct encoding wtERAB/HADH II (Fig. 4A, upper panel) . However, cotransfection of COS cells with pcDNA3/mutERAB ϩ pAdlox/ ␤APP(V717G) did not show an increase in cytoplasmic histoneassociated DNA fragments, compared with cells transfected with pAdlox/␤APP(V717G) alone or other controls (Fig. 4B) . Furthermore, using the RAI, cells cotransfected to overexpress ␤APP(V717G) and mutERAB did not display an increase in RAI ERAB (Ϸ12%) or RAI ␤APP (Ϸ9%), compared with RAI 0 (Ϸ5%) (Fig. 4D) . Thus, although mutERAB (Y168G/K172G) was expressed similarly to wtERAB/HADH II, the enzymati-FIG. 7. Subcellular fractionation of neuroblastoma cells either transfected with pcDNA3/wtERAB/HADH II alone (A), cotransfected with pcDNA3/wtERAB ϩ pAdlox/␤APP(V717G) (B), transfected with pcDNA3/mutERAB alone (C), cotransfected with pcDNA3/mutERAB ϩ pAdlox/␤APP(V717G) (D), or cotransfected with pcDNA3/ wtERAB/HADH II ϩ pMT/wt␤APP (E). Neuroblastoma cells were transfected/cotransfected with the indicated constructs and processed as described in the text. Each fraction prepared from nontransfected neuroblastoma cells was also subjected to Western blotting using antibodies to ERAB/HADH II and/or to proteins associated with specific subcellular structures: GRP78/Bip for endoplasmic reticulum (F, lanes  1 and 2) , RAGE for plasma membrane (G, lane 4) , and cytochrome c for mitochondria (H, lane 6).
cally inactive form was ineffective for potentiating apoptosis in COS cells overexpressing ␤APP(V717G). Comparable results were observed when mutERAB(Y168G/K172G) was replaced with the two other mutant forms of ERAB/HADH II, Y168G and K172G (data not shown).
ERAB/HADH II Oxidation of Linear Alcohol Substrates and the Effect of A␤-To probe mechanisms through which ERAB/ HADH II induced its toxic effects in an A␤-rich environment, possible dehydrogenation of a range alcohol substrates was studied, based on the hypothesis that such activity might give rise to aldehydes with associated toxic properties. Using a series of alcohols with carbon chains of differing lengths, ERAB/HADH II-dependent oxidation was evaluated; the most favorable catalytic efficiencies were seen for the stereoisomers of 2-octanol, with k cat /K m of Ϸ540 -1400 M Ϫ1 s Ϫ1 and K m values of Ϸ40 -80 mM ( Fig. 2B and Table I ). ERAB/HADH II activity toward steroid substrates was studied using 17␤-estradiol (Fig.  2C) , NAD ϩ -dependent dehydrogenation occurred with a catalytic efficiency (k cat /K m ) of Ϸ7.4 ϫ 10 5 M Ϫ1 s Ϫ1 had a K m value of Ϸ14 M (see Table I ). It is significant that this latter catalytic efficiency is only about 4-fold less than that seen in the reduction of S-acetoacetyl-CoA (Table I) . These data were consistent with the concept that ERAB/HADH II could effectively metabolize a range of alcohols, although the activity toward linear alcohol substrates was less than that as an hydroxysteroid dehydrogenase.
FIG. 8. Expression of MDA and HNE epitopes in COS cells expressing wt or mutERAB/HADH II with or without ␤APP(V717G). COS cells were transiently transfected with pcDNA3/wtERAB or pcDNA3/mutERAB(Y168G/K172G) either alone or in the presence of pAdlox/ ␤APP(V717G). Cultures were fixed and stained with antibodies to MDA and ERAB/HADH II, or HNE and ERAB/HADH II. Panels represent the following. A, I-IX, MDA and ERAB/HADH II staining (wtERAB/HADH II): cells were transfected with pcDNA3/wtERAB alone (I-III), transfected with pAdlox/␤APP(V717G) alone (IV-VI), or cotransfected with pcDNA3/wtERAB ϩ pAdlox/␤APP(V717G) (VII-IX). Cultures were stained to visualize either ERAB/HADH II alone (green) (III, VI, and IX), MDA alone (red) (II, V, and VIII) or ERAB/HADH II ϩ MDA antigens (I, IV, and VII). A, X-XV, MDA and ERAB/HADH II (mutERAB) staining: cells were transfected with pcDNA3/mutERAB alone (XIII-XV) or cotransfected with pcDNA3/mutERAB ϩ pAdlox/␤APP(V717G) (X-XII). Cultures were stained to visualize either ERAB/HADH II alone (green) (XII and XV), MDA alone (red) (XI and IV) or ERAB/HADH II ϩ MDA antigens (X and XIII). B, I-IX, HNE and ERAB/HADH II (wtERAB) staining: staining was identical to panel A, except that antibody to HNE was used in place of antibody to MDA. B, X-XV, HNE and ERAB/HADH II staining (mutERAB): staining was identical to panel A, except that antibody to HNE was used in place of antibody to MDA. In each case, the antigens visualized by immunostaining (labeled above the figure) and the gene products overexpressed by transfection (labeled on the far left) are indicated.
Because enzymatic activity of ERAB/HADH II was essential for potentiation of A␤ cytotoxicity, it was possible that the amyloidogenic peptide enhanced the enzymatic activity of ERAB/HADH II or modulated substrate specificity, possibly favoring linear alcohols with resultant augmented formation of aldehydes. Addition of increasing concentrations of synthetic A␤(1-40) to ERAB/HADH II diminished NADH-dependent reduction of S-acetoacetyl-CoA (Fig. 5A) . Inhibition fit to a onesite competitive model with K i Ϸ 1.6 Ϯ 0.5 M (34). Similarly, A␤ suppressed ERAB/HADH II-mediated, NAD ϩ -dependent oxidation of octanol (K i Ϸ 2.6 Ϯ 0.3 M; Fig. 5B ) and 17␤estradiol (K i Ϸ 3.2 Ϯ 0.2 M; Fig. 5C ). Comparable results were obtained when A␤(1-42) was used in place of A␤(1-40) (data not shown). Such levels of A␤ that attenuated ERAB/HADH II activity toward each of these substrates were considerably higher than those required to occupy A␤ binding sites on ERAB/HADH II; the K d for A␤ binding to ERAB/HADH II was Ϸ40 -70 nM (see Fig. 3B ). This was an important consideration, because intracellular A␤ would more likely be present at nanomolar levels than in the micromolar range. Thus, there is probably a secondary effect of binding of additional molecules of A␤ (or perhaps aggregated/fibrillar A␤) to ERAB/HADH II, but these effects are distinct from the lower amounts of A␤ that occupy ERAB/HADH II binding sites.
Change in Subcellular Distribution of ERAB/HADH II and Generation of Reactive Aldehydes in an A␤-rich Environment-In a previous study, we observed that exogenous A␤ induced a change in the subcellular distribution of ERAB/ HADH II in neuroblastoma cells (15) . This suggested the possibility that ERAB/HADH II might find different substrates and/or activate enzyme systems following its transposition to new sites within the cell. Because of the association of oxidant stress with AD (9, 25-31), we considered the possibility that following translocation within the cell, ERAB/HADH II participated in events generating reactive aldehydes, MDA and/or HNE, both of which have been observed in the brain of AD patients (26 -32) . First, subcellular distribution of ERAB/HADH II in neuroblastoma cells transfected to overexpress ERAB/HADH II alone or ERAB/HADH II ϩ ␤APP(V717G) was studied. Confocal microscopy of neuroblastoma cells transfected with pcDNA3/ERAB, either wtERAB or mutERAB(Y168G/K172G), displayed ERAB/HADH II principally in endoplasmic reticulum and mitochondria (Fig. 6 , A-F, shows results with wtERAB). The distribution of ERAB/ HADH II (Fig. 6 , C and F) overlapped (Fig. 6, A and D) , in part, with an endoplasmic reticulum marker, PDI (Fig. 6B ) and a mitochondrial marker (Fig. 6E ). Consistent with these results, subcellular fractionation of neuroblastoma cells transfected with pcDNA3/wtERAB showed ERAB/HADH II antigen to be principally in fractions enriched for mitochondrial and endoplasmic re- ticulum markers (Fig. 7A ). The distribution of mutERAB in neuroblastoma cells similarly transfected with pcDNA3/mutERAB was comparable to that observed with wtERAB/HADH II, as seen in subcellular fractionation studies (Fig. 7C ) and by confocal microscopy (data not shown). Cotransfection of neuroblastoma cells with pcDNA3/wtERAB and pAdlox/␤APP(V717G) displayed a different pattern of ERAB/HADH II antigen (Fig. 6, G--L) . By confocal microscopy the altered distribution of ERAB/HADH II in cotransfectants (Fig. 6, I and L) was evident, with lesser amounts in endoplasmic reticulum (Fig. 6, G and H) , although it was still in mitochondria ( Fig. 6, J and K) . Strikingly, in cotransfectants with pcDNA3/wtERAB and pAdlox/␤APP(V717G), ERAB/HADH II antigen seemed to be present in multiple sites within the cell, including the plasma membrane. In general, ERAB/HADH II antigen appeared to be more diffusely distributed in cotransfectants with some antigen in cell membrane, cytosol, and nuclear membrane and, in certain instances, associated with the nucleus. Subcellular fractionation studies showed a shift in ERAB/HADH II antigen to fractions rich in plasma membrane markers in cotransfectants (Fig. 7B ). Similar results were obtained when mutERAB(Y168G/ K172G) was overexpressed in place of wtERAB/HADH II (Fig. 7D ). COS cells subjected to the cotransfection procedure and the same analysis as described above showed similar, though less striking results. Experiments in which wt␤APP was overexpressed along with wild-type ERAB/HADH II also showed translocation of ERAB/ HADH II from endoplasmic reticulum-associated to plasma membrane-associated fractions (Fig. 7E ), although to a somewhat lesser extent than was seen with mutant ␤APP(V717G).
Having established that ERAB/HADH II changed its distribution in cells cotransfected to overexpress both ERAB/HADH II and ␤APP(V717G), we next sought to determine whether reactive aldehydes (MDA or HNE) were formed under these conditions. COS cells overexpressing wtERAB/HADH II and ␤APP(V717G) were studied for MDA and HNE epitopes using murine monoclonal antibodies and confocal microscopy. Cultures expressing either wtERAB/HADH II or ␤APP(V717G) alone showed no increase in MDA (Fig. 8A, I-III and IV-VI, respectively) or HNE antigen (Fig. 8B, I-III and IV-VI, respectively). In contrast, cultures expressing both wtERAB/HADH II and ␤APP(V717G) showed abundant MDA (Fig. 8A , VII-IX) and HNE antigen (Fig. 8B , VII-IX; quantitative analysis of this immunocytochemical data is shown in Fig. 9, A and C) . In cotransfectants, the distribution of MDA and ERAB/HADH II (Fig. 8A, VII) , or HNE and ERAB/HADH II (Fig. 8B, VII) antigen appeared to overlap, at least in part. ERAB/HADH II (Fig. 8, A and B, IX) and HNE or MDA (Fig. 8, A and B, VIII) were present in the cell membrane, as well as more diffusely throughout the cell. These experiments were also performed with mutERAB(Y168G/K172G) in place of wtERAB/HADH II (Fig. 8, A and B, X-XV) . In contrast to the wild-type enzyme, (Fig. 8, A and B , XII and XV) did not generate elevated levels of either MDA or HNE epitopes (Fig. 8, A and B , XI and XIV, and Fig. 9 ). Thus, the integrity of the active site of ERAB/HADH II is required to support generation of reactive aldehydes, such as malondialdehyde and 4-hydroxynonenal, in cells cotransfected with ␤APP(V717G). Further experiments were performed in which cultures were transfected to overexpress wt␤APP (in place of mutant ␤APP) and wtERAB (Fig. 9,  B and D) . In these studies as well, there was an increase, although to a lesser extent, in generation of reactive aldehyde epitopes in cells expressing wtERAB ϩ wt␤APP compared with cultures expressing either wtERAB or wt␤APP alone. For the latter studies, the increase in HNE epitopes (Fig. 9D ) was more striking than that for MDA epitopes (Fig. 9B) , although over many experiments, it was evident that both reactive aldehydes were produced at higher levels in cells cotransfected to overexpress wtERAB ϩ wt␤APP than in cultures expressing either wtERAB or wt␤APP alone.
DISCUSSION
The properties of ERAB/L-3-hydroxyacyl-CoA dehydrogenase type II reveal an intriguing dichotomy for cellular homeostasis. On the one hand, enzyme activity as an L-3-hydroxyacyl-CoA dehydrogenase is consistent with ERAB/HADH II participation in metabolic homeostasis, namely in the fatty acid ␤-oxidation pathway. This concept is in accordance with previous reports demonstrating that bovine (17, 18) and, more recently, human (21) L-3-hydroxyacyl-CoA dehydrogenase reversibly catalyze the third reaction of the fatty acid ␤-oxidation cycle in vitro. Although inherited deficiencies of enzymes involved in fatty acid ␤-oxidation clearly have serious clinical consequences (19, 20) , including a report of short chain 3-hydroxyacyl-CoA dehydrogenase deficiency (47) , whether ERAB/HADH II has an important role in normal metabolic balance remains to be determined. ERAB/HADH II also has the capacity to dehydrogenate alcohol functions, including a range of linear alcohols, as well as 17␤-estradiol. Although efficiency of the enzyme is less for the latter reactions than as an HADH, these data emphasize the potentially broad capacity of ERAB/HADH II to dehydrogenate a range of alcohol substrates. Whereas the physiologic significance of this property of ERAB/HADH II is not clear at this time, the potential of ERAB to metabolize 17␤-estradiol, a neuro-and vascular-protective hormone (48 -51) , deserves further study. The reason for the apparent lack of ERAB/ HADH type II activity as a 17␤-hydroxysteroid dehydrogenase in the experiments of He et al. (21) may reflect differences in assay conditions and/or in the nature of the E. coli-derived protein.
From another vantage point, ERAB/HADH II takes on a quite different role in cells subjected to an environment rich in A␤. Previously (15) , we found that cell stress, following exposure of neuroblastoma cells to synthetic A␤, was increased in cultures transfected to overexpress ERAB/HADH II. Cotransfection of the same ERAB/HADH II-expressing cells with a construct specifically generating cytosolic A␤ similarly enhanced cytotoxicity (15) . Consistent with these data, blockade of ERAB/HADH II, following intracellular introduction of anti-ERAB F(abЈ) 2 using a liposome-based system, had a protective effect in the presence of A␤ (15) . Because these previous experiments involved nonphysiologic exposure of cultured cells to A␤ and intracellular loading of foreign antibody fragments, we have extended our observations using a system in which cultured cells are simultaneously cotransfected with constructs encoding ERAB/HADH II and mutant ␤APP(V717G). This system allows endogenous overexpression of both genes without other interventions; such cells suffer intense stress, evidenced by DNA fragmentation and generation of reactive aldehydes (MDA/HNE epitopes). Our results are unlikely to represent a general "endoplasmic reticulum stress response," (52, 53) as similar cotransfection studies with ERAB/HADH II mutants devoid of enzymatic activity did not induce cell damage, although the level of expression of the transfected constructs was comparable.
Data from the cotransfection systems with pcDNA3/wtERAB and pAdlox/␤APP(V717G) suggest that ERAB/HADH II and, presumably, the product of cellular ␤APP(V717G) metabolism, A␤, interact with cytotoxic consequences for the host cell. The molecular mechanisms underlying such an interaction must be clarified in detail, because direct ERAB/HADH II binding to A␤ would suggest that A␤ generated in the lumen of the endoplasmic reticulum or other membrane-bound compartments could interact with ERAB/HADH II, the latter likely to be present on the cytosolic side of endoplasmic reticulum and in mitochondria. The apparently reduced potentiation of cytotoxicity when cultures were cotransfected with pcDNA3/wtERAB ϩ pMT/ wt␤APP, the latter in place of ␤APP(V717G), suggests that high levels of cell-associated A␤(1-42) generated with the mutant form of ␤APP (36) accentuate toxicity in the presence of ERAB/HADH II. These data are also consistent with the possibility of an interaction, either direct or indirect, between ERAB/HADH II and A␤. However, regardless of the precise mechanism by which ERAB/HADH II and A␤ interact, our data using this cotransfection system provide strong support for the concept that ERAB/HADH II enzymatic activity can exert deleterious effects in cells overexpressing ␤APP. Thus, three ERAB/HADH II mutants that were devoid of enzymatic activity and expressed comparably to wtERAB/HADH II showed dramatically reduced DNA fragmentation in cotransfection experiments with pAdlox/␤APP(V717G), compared with native ERAB/HADH II. Because A␤ interaction with these enzymatically inactive ERAB/HADH II mutants was similar to that observed with wtERAB/HADH II, the enzymatic activity of ERAB must be differentiated from those determinants that mediate binding of A␤. In accordance with this concept is our finding that ERAB/HADH II binding sites for A␤ are halfmaximally occupied at a peptide concentration of Ϸ40 -70 nM, whereas A␤ suppression of ERAB/HADH II enzymatic activity occurs at much higher concentrations, Ϸ2-3 M. The latter levels of A␤ are unlikely to be present within cells, and, taken together, the data suggest that ERAB/HADH II binding to A␤ may modulate other properties of the molecule, such as its localization within the cell.
We hypothesize that when lower levels of A␤ are present in the brain, cytotoxicity may not be due solely to the amyloidogenic peptide itself, but may be amplified by cellular cofactors such as ERAB/HADH II. By directly forming a complex with ERAB/HADH II and/or indirectly (through undefined A␤-mediated changes in cellular properties) modulating enzymatically active ERAB/HADH II function/localization, we increased cellular vulnerability. Taken together, the combination of A␤ binding properties and generalized alcohol dehydrogenase activity, in addition to HADH activity, lead us to propose the new name A␤ binding alcohol dehydrogenase or ABAD to better describe the unusual properties of the enzyme previously referred to as ERAB or HADH II.
